Literature DB >> 11179346

Immune response to infection with Mycobacterium ulcerans.

T M Gooding1, P D Johnson, D E Campbell, J A Hayman, E L Hartland, A S Kemp, R M Robins-Browne.   

Abstract

Mycobacterium ulcerans is a slow-growing, acid-fast bacillus that causes chronic necrotizing skin ulcers known as Buruli ulcers. Previously reported information on immunity to this mycobacterium is limited. We examined immune responses to M. ulcerans and M. bovis BCG in patients with M. ulcerans disease and in 20 healthy control subjects (10 tuberculin test positive and 10 tuberculin test negative). Cell-mediated immunity was assessed by stimulating peripheral blood mononuclear cells (PBMC) with whole mycobacteria and then measuring PBMC proliferation and the production of gamma interferon (IFN-gamma). Humoral immunity was assessed by immunoblotting. PBMC from all subjects showed significantly greater proliferation and IFN-gamma production in response to stimulation with living mycobacteria compared with killed cells. However, PBMC from subjects with past or current M. ulcerans disease showed significantly reduced proliferation and production of IFN-gamma in response to stimulation with live M. ulcerans or M. bovis than PBMC from healthy, tuberculin test-positive subjects (P < 0.001) and showed results in these assays comparable to those of tuberculin test-negative subjects (P > 0.2). Serum from 9 of 11 patients with M. ulcerans disease, but no control subject, contained antibodies to M. ulcerans. The results indicate that patients with M. ulcerans infection mount an immune response to M. ulcerans as evidenced by antibody production, but they demonstrate profound systemic T-cell anergy to mycobacterial antigens. These findings may explain some of the distinct clinical and pathological features of M. ulcerans-induced disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11179346      PMCID: PMC98075          DOI: 10.1128/IAI.69.3.1704-1707.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  18 in total

1.  Proliferation of distinct human T cell subsets in response to live, killed or soluble extracts of Mycobacterium tuberculosis and Myco. avium.

Authors:  S Esin; G Batoni; G Källenius; H Gaines; M Campa; S B Svenson; R Andersson; H Wigzell
Journal:  Clin Exp Immunol       Date:  1996-06       Impact factor: 4.330

2.  Mycobacterial crossreactivity of M. tuberculosis reactive T cell clones from naturally converted PPD positive healthy subjects.

Authors:  F Oftung; E Borka; G Kvalheim; A S Mustafa
Journal:  FEMS Immunol Med Microbiol       Date:  1998-03

Review 3.  Mycobacterium ulcerans infection.

Authors:  T S van der Werf; W T van der Graaf; J W Tappero; K Asiedu
Journal:  Lancet       Date:  1999-09-18       Impact factor: 79.321

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection.

Authors:  M J Newport; C M Huxley; S Huston; C M Hawrylowicz; B A Oostra; R Williamson; M Levin
Journal:  N Engl J Med       Date:  1996-12-26       Impact factor: 91.245

6.  Circulating immune complexes in human tuberculosis sera: demonstration of specific antibodies against Mycobacterium tuberculosis glycolipid (DAT, PGLTb1, LOS) antigens in isolated circulating immune complexes.

Authors:  N Simonney; J M Molina; M Molimard; E Oksenhendler; P H Lagrange
Journal:  Eur J Clin Invest       Date:  1997-02       Impact factor: 4.686

7.  Partial interferon-gamma receptor signaling chain deficiency in a patient with bacille Calmette-Guérin and Mycobacterium abscessus infection.

Authors:  R Döffinger; E Jouanguy; S Dupuis; M C Fondanèche; J L Stephan; J F Emile; S Lamhamedi-Cherradi; F Altare; A Pallier; G Barcenas-Morales; E Meinl; C Krause; S Pestka; R D Schreiber; F Novelli; J L Casanova
Journal:  J Infect Dis       Date:  2000-01       Impact factor: 5.226

8.  Serologic response to culture filtrate antigens of Mycobacterium ulcerans during Buruli ulcer disease.

Authors:  K M Dobos; E A Spotts; B J Marston; C R Horsburgh; C H King
Journal:  Emerg Infect Dis       Date:  2000 Mar-Apr       Impact factor: 6.883

9.  The emergence of Mycobacterium ulcerans infection near Melbourne.

Authors:  P D Johnson; M G Veitch; D E Leslie; P E Flood; J A Hayman
Journal:  Med J Aust       Date:  1996-01-15       Impact factor: 7.738

10.  The production and preliminary investigation of Burulin, a new skin test reagent for Mycobacterium ulcerans infection.

Authors:  J L Stanford; W D Revill; W J Gunthorpe; J M Grange
Journal:  J Hyg (Lond)       Date:  1975-02
View more
  42 in total

1.  Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression.

Authors:  Alexandra G Fraga; Andrea Cruz; Teresa G Martins; Egídio Torrado; Margarida Saraiva; Daniela R Pereira; Wayne M Meyers; Françoise Portaels; Manuel T Silva; António G Castro; Jorge Pedrosa
Journal:  Infect Immun       Date:  2010-10-25       Impact factor: 3.441

2.  IFN-gamma induces the erosion of preexisting CD8 T cell memory during infection with a heterologous intracellular bacterium.

Authors:  Renu Dudani; Kaja Murali-Krishna; Lakshmi Krishnan; Subash Sad
Journal:  J Immunol       Date:  2008-08-01       Impact factor: 5.422

3.  Prophylactic effect of mycobacterium bovis BCG vaccination against osteomyelitis in children with Mycobacterium ulcerans disease (Buruli Ulcer).

Authors:  F Portaels; J Aguiar; M Debacker; C Steunou; C Zinsou; A Guédénon; W M Meyers
Journal:  Clin Diagn Lab Immunol       Date:  2002-11

Review 4.  Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans.

Authors:  Caroline Demangel; Timothy P Stinear; Stewart T Cole
Journal:  Nat Rev Microbiol       Date:  2009-01       Impact factor: 60.633

5.  Mycobacterium bovis BCG vaccination as prophylaxis against Mycobacterium ulcerans osteomyelitis in Buruli ulcer disease.

Authors:  F Portaels; J Aguiar; M Debacker; A Guédénon; C Steunou; C Zinsou; W M Meyers
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

6.  Differences in virulence and immune response induced in a murine model by isolates of Mycobacterium ulcerans from different geographic areas.

Authors:  R Hurtado Ortiz; D Aguilar Leon; H Orozco Estevez; A Martin; J Luna Herrera; L Flores Romo; F Portaels; R Hernandez Pando
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

7.  Cytokine profiles of patients infected with Mycobacterium ulcerans and unaffected household contacts.

Authors:  Travis M Gooding; Paul D R Johnson; May Smith; Andrew S Kemp; Roy M Robins-Browne
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

8.  Serological evaluation of Mycobacterium ulcerans antigens identified by comparative genomics.

Authors:  Sacha J Pidot; Jessica L Porter; Laurent Marsollier; Annick Chauty; Florence Migot-Nabias; Cyril Badaut; Angèle Bénard; Marie-Therese Ruf; Torsten Seemann; Paul D R Johnson; John K Davies; Grant A Jenkin; Gerd Pluschke; Timothy P Stinear
Journal:  PLoS Negl Trop Dis       Date:  2010-11-02

9.  Antioxidants protect keratinocytes against M. ulcerans mycolactone cytotoxicity.

Authors:  Alvar Grönberg; Louise Zettergren; Kerstin Bergh; Mona Ståhle; Johan Heilborn; Kristian Angeby; Pamela L Small; Hannah Akuffo; Sven Britton
Journal:  PLoS One       Date:  2010-11-04       Impact factor: 3.240

10.  Family relationship, water contact and occurrence of Buruli ulcer in Benin.

Authors:  Ghislain Emmanuel Sopoh; Yves Thierry Barogui; Roch Christian Johnson; Ange Dodji Dossou; Michel Makoutodé; Sévérin Y Anagonou; Luc Kestens; Françoise Portaels
Journal:  PLoS Negl Trop Dis       Date:  2010-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.